Evidence mapPaperPMID 41286314Full record

ArticleScientific reports2025

lncRNA RP11-199F11.2 promotes high-grade serous ovarian cancer cell proliferation by regulating cuproptosis through FDX1.

Shishi Xu, Linping Wang, Yingying Wu, Yufang Xia, Lingzhi Wang, Xiao Yu, Xin Sun, Yanhui Lou

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shishi Xu *Department of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Linping Wang *Weihai Maternal and Child Health Hospital Affiliated to Qingdao University, Weihai, 264200, China.
Yingying WuDepartment of Obstetrics and Gynaecology, Shanghai First Maternity and Infant Hospital, Shanghai, 201204, China.
Yufang XiaDepartment of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Lingzhi WangDepartment of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Xiao YuDepartment of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Xin SunDepartment of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Yanhui LouDepartment of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. louyh@qdu.edu.cn.

Funding

the Shinan District Science and Technology Program in Qingdao, Shandong Province, China 2022-2-006-YY
6 · The paper itself

Abstract

To elucidate the expression characteristics of the long noncoding RNA RP11-199F11.2 (RP11) in high-grade serous ovarian cancer (HGSOC) and its potential mechanism of regulating cancer progression via the copper-death pathway, and to evaluate the therapeutic potential of the copper ion carrier ES-Cu. The interaction between RP11 and FDX1 was predicted via bioinformatics; the posttranscriptional inhibition of FDX1 by RP11 was verified via qRT‒PCR and Western blotting; the effects of RP11 knockdown/overexpression on proliferation were evaluated in in vitro and in subcutaneous xenograft cancer models; ES-Cu was used to induce copper death, and cell death patterns and circulating inflammatory cytokines were detected via flow cytometry and ELISA. RP11 was significantly highly expressed in HGSOC tissues and was positively correlated with FIGO stage and lymph node metastasis (P < 0.01). Mechanistically, bioinformatic analysis suggests that RP11 may binds the 3'-UTR of FDX1 to reduce its translation, thereby limiting copper death and increased cell proliferation. ES-Cu treatment restored FDX1 expression, re-activated copper death, and reduced tumour volume by 68% (P < 0.001) without detectable histological toxicity. RP11 is associated with inhibits copper death and modulation of local inflammatory milieu by suppressing FDX1, which may contribute to HGSOC progression. ES-Cu re-activates the FDX1-copper-death axis, providing a potential strategy for combining copper-death induction with immunomodulation in HGSOC.

Indexed as

CopperCystadenocarcinoma, SerousOvarian NeoplasmsRNA, Long NoncodingAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMiddle AgedCopperRNA, Long NoncodingCuproptosisFDX1High-grade serous ovarian cancerInflammatory microenvironmentlncRNA RP11-199F11.2

Identifiers

PMID41286314
PMCPMC12749927

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.